Clinical trials: Demyelinating Disorder
Multiple Sclerosis, Relapsing-Remitting
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
The purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- SCLEROLYM (NCT02427776)
- Testing
- Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
- Where
- 3 sites in Belgium
- Volunteers
- 2 people
- Sponsor
- Imcyse SA
Multiple Sclerosis
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the…
- Trial name
- NCT05170126
- Where
- 3 sites in United States, Germany
- Volunteers
- 1,182 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Alzheimer Disease, Mild Cognitive Impairment
Longitudinal Cognitive Assessment by BoCA
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia
- Trial name
- BoCA (NCT04114994)
- Testing
- Boston Cognitive Assessment (BoCA)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Light LLC
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting…
- Trial name
- (DECIDE) (NCT01064401)
- Testing
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a
- Where
- 228 sites in United States, Argentina and 26 more
- Volunteers
- 1,841 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis (RRMS)
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
The primary objective is to determine adherence to Rebif® New Formulation administered by RebiSmart during 12 weeks of therapy in patients with RRMS.
- Trial name
- SCANSMART (NCT01125475)
- Testing
- RebiSmart
- Where
- Norway
- Volunteers
- 61 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
EPID Multiple Sclerosis Pregnancy Study
Multiple Sclerosis (MS) is the most common chronic neurologic disability in young adult females in their childbearing ages. Little evidence is available regarding the association between exposure to IFN-beta (β) products and…
- Trial name
- NCT02749396
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd
- Where
- Finland
- Volunteers
- 2,089 people, healthy volunteers welcome
- Sponsor
- Bayer
Spasticity, Multiple Sclerosis
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
- Trial name
- NCT00914290
- Testing
- IPX056, Baclofen IR
- Where
- 11 sites in United States
- Volunteers
- 23 people
- Sponsor
- Impax Laboratories, LLC
Healthy, Multiple Sclerosis
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers
The purpose of this study is to characterize the pharmacokinetic (PK) profile, safety, and tolerability of peginterferon beta-1a (BIIB017) delivered by the single-use autoinjector or prefilled syringe (PFS) in healthy volunteers…
- Trial name
- NCT01610310
- Testing
- BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS), BIIB017 (peginterferon beta-1a) Autoinjector
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Biogen
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Opioid Dependence, Alcohol Dependence
A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.
- Conditions
- Opioid Dependence, Alcohol Dependence, Multiple Sclerosis
- Trial name
- NCT05620940
- Testing
- Vivitrol Injectable Product, IVL3004, IVL4002
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Inventage Lab., Inc.
Spasticity, Multiple Sclerosis
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
- Trial name
- NCT01868048
- Testing
- Sativex
- Sponsor
- GW Research Ltd
Relapsing-Remitting Multiple Sclerosis
Natalizumab (Tysabri) Re-Initiation of Dosing
The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to…
- Trial name
- STRATA (NCT00297232)
- Testing
- Natalizumab
- Where
- 112 sites in Australia, Belgium and 19 more
- Volunteers
- 1,094 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…
- Trial name
- RELIEF (NCT02064816)
- Testing
- Rebif®
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis
Clinical study BCD-132-4/MIRANTIBUS is an international, multicenter, randomized, double-blind, double-masked study using an active reference drug (teriflunomide).
- Trial name
- MIRANTIBUS (NCT05385744)
- Testing
- BCD-132, Teriflunomide
- Where
- Russia
- Volunteers
- 336 people
- Sponsor
- Biocad
Multiple Sclerosis
Effectiveness of Ofatumumab in Real-world Practice
This study used a retrospective single cohort pre-post design on Optum® Clinformatics® Data Mart (CDM) data from 20 August 2019 to 31 December 2023 (study period).
- Trial name
- NCT06760624
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Novartis Pharmaceuticals
Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Central Pain Study for ABX-1431
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Trial name
- NCT03138421
- Testing
- ABX-1431 HCl
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Abide Therapeutics
Relapsing-Remitting Multiple Sclerosis
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012…
- Trial name
- TOLERATE (NCT02125604)
- Testing
- dimethyl fumarate
- Where
- 19 sites in Germany
- Volunteers
- 214 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera
The primary objective of the study is to describe absolute lymphocyte count (ALC) reconstitution after Dimethyl fumarate (DMF) discontinuation, in Relapsing-Remitting Multiple Sclerosis (RRMS) participants with lymphopenia.
- Trial name
- Lympho-TEC (NCT04756687)
- Testing
- Dimethyl fumarate
- Where
- 32 sites in France
- Volunteers
- 1,507 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Study of Electrical Impedance Myography (EIM) in ALS
This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the…
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Charcot-Marie-Tooth Disease, Multiple Sclerosis
- Trial name
- NCT02011204
- Testing
- Electrical impedance myography (EIM)
- Where
- 6 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Skulpt, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.